Brca Mutated Ovarian Cancer Therapeutics
1. Lynparza patent expiration
Treatment: Adjuvant treatment of patients with gbrca-mutated human epidermal growth factor receptor 2 (her2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy...
LYNPARZA's oppositions filed in EPO
LYNPARZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7151102 | ASTRAZENECA | Phthalazinone derivatives |
Apr, 2022
(3 years ago) | |
| US7981889 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(1 year, 2 months ago) | |
| US7449464 | ASTRAZENECA | Phthalazinone derivatives |
Sep, 2027
(1 year, 7 months from now) | |
| US8247416 | ASTRAZENECA | Phthalazinone derivative |
Sep, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143241 | ASTRAZENECA | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(1 year, 7 months from now) | |
| US8912187 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 9 months ago) | |
| US11970530 | ASTRAZENECA | Methods of treating homologous recombination deficient cancer |
Oct, 2041
(15 years from now) | |
| US9566276 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 9 months ago) | |
| US8859562 | ASTRAZENECA | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(5 years from now) | |
| US8071579 | ASTRAZENECA | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(1 year, 7 months from now) | |
| US9169235 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 9 months ago) | |
| US11975001 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| US11633396 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| US8475842 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Dec, 2029
(3 years from now) | |
| US12048695 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| US12178816 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| US12144810 | ASTRAZENECA | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Oct, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Product(NP) | Aug 17, 2020 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| New Indication(I-885) | Mar 11, 2025 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| New Indication(I-914) | May 31, 2026 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 17 August, 2017
Dosage: TABLET; CAPSULE
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
2. Rubraca patent expiration
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation; A method for treating epithelial ovarian, fallopian tu...
RUBRACA's oppositions filed in EPO
RUBRACA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6495541 | PHARMAAND | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
Nov, 2023
(2 years ago) | |
| US8754072 | PHARMAAND | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(5 years from now) | |
| US9045487 | PHARMAAND | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8143241 | PHARMAAND | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(1 year, 7 months from now) | |
| US7351701 | PHARMAAND | Therapeutic compounds |
Jul, 2024
(1 year, 5 months ago) | |
| US7531530 | PHARMAAND | Therapeutic compounds |
Jul, 2024
(1 year, 5 months ago) | |
| US9861638 | PHARMAAND | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(5 years from now) | |
| US8071579 | PHARMAAND | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(1 year, 7 months from now) | |
| US8859562 | PHARMAAND | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(5 years from now) | |
| US10130636 | PHARMAAND | High dosage strength tablets of rucaparib |
Aug, 2035
(9 years from now) | |
| US10278974 | PHARMAAND | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one |
Feb, 2031
(5 years from now) | |
| US9987285 | PHARMAAND | High dosage strength tablets of rucaparib |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-772) | Apr 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2021 |
| New Indication(I-830) | May 15, 2023 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2023 |
| Orphan Drug Exclusivity(ODE-126) | Dec 19, 2023 |
| Orphan Drug Exclusivity(ODE-168) | Apr 06, 2025 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
NCE-1 date: 19 December, 2020
Market Authorisation Date: 19 December, 2016
Dosage: TABLET
More Information on Dosage
RUBRACA family patents